

REMARKS

Applicants submit herewith a substitute Sequence Listing in computer and paper form, in accordance with 37 C.F.R. §1.821-1.825. The content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same and do not include new matter.

The specification has been amended to including sequence identifiers for SEQ ID NOS:69-73, 107, 115-117, and 126-128 in the Brief Description of the Drawings. The Sequence Listing has also been amended to incorporate SEQ ID NOS:126-128 from Figure 15. SEQ ID NO:126 corresponds to the reverse complement of trans-spliced product comprising cystic fibrosis transmembrane regulator-derived sequences and His tag sequences. SEQ ID NOS:127 and 128 correspond to the 3' and 5' ends of the trans-spliced product comprising cystic fibrosis transmembrane regulator-derived sequences and His tag sequences, respectively. Support for the amendments can be found throughout the specification and claims as originally filed and there is no new matter added as a consequence of the amendments to the specification and sequence listing.

CONCLUSION

Applicants do not believe that any fee is required in connection with the submission of this paper. However, should any fee be required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

  
Rochelle K. Seide

PTO Registration No. 32,300

Carmella L. Stephens

PTO Registration No. 41,328

Attorneys for Applicant

BAKER BOTTS, L.L.P.

30 Rockefeller Plaza

New York, NY 10112

(212) 408-2539